Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15347416 | 1.00 | SLC6A9 (0.43) | SLC6A9USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL23235715 | 0.99 | SLC6A9 (0.44) | SLC6A9USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL13812253 | 0.99 | SLC6A9 (0.44) | SLC6A9USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL3783647 | 0.90 | NR1H2 (0.39) | SLC6A9USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL3179712 | 0.86 | NR1H2 (0.41) | USP2SMN1; SMN2NR1H2HPGDMEN1 | |
| SCHEMBL3179703 | 0.86 | NR1H2 (0.41) | USP2SMN1; SMN2NR1H2HPGDMEN1 | |
| SCHEMBL3315088 | 0.84 | NR1H2 (0.40) | USP2SMN1; SMN2NR1H2MEN1ALDH1A1 | |
| SCHEMBL3319602 | 0.84 | NR1H2 (0.40) | USP2SMN1; SMN2NR1H2MEN1ALDH1A1 | |
| SCHEMBL17477191 | 0.84 | NR1H2 (0.44) | USP2SMN1; SMN2NR1H2HPGDMEN1 | |
| SCHEMBL17477192 | 0.84 | NR1H2 (0.44) | USP2SMN1; SMN2NR1H2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940841-B9 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2017-04-19 | — | — | EP | disclosed |
| US-20170050988-A1 | DOTAM DERIVATIVES FOR THERAPEUTIC USE | SANOFI (FR) | 2017-02-23 | — | — | US | disclosed |
| EP-1940841-B1 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2016-12-07 | — | — | EP | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | KLK3, IGF1R, GIPR | SLC6A9 4319/4885USP2 3392/4885SMN1; SMN2 4882/4885 |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | SLC6A9 2876/4885USP2 774/4885SMN1; SMN2 4296/4885 |
| US-20170050988-A1 | DOTAM DERIVATIVES FOR THERAPEUTIC USE | SSTR2, SSTR5, SSTR3 | SLC6A9 358/4885USP2 4447/4885SMN1; SMN2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.